Management ChangeJun 15, 2026, 07:31 AM
Immuneering Appoints Andrew Gengos as New CFO
AI Summary
Immuneering Corporation announced the appointment of Andrew Gengos as its new Chief Financial Officer, effective July 16, 2026. Mr. Gengos brings over 25 years of leadership experience in biotech, having most recently served as CFO of Terns Pharmaceuticals, which was acquired by Merck & Co., Inc. for $6.7 billion. He will be responsible for Immuneering's financial strategy, capital allocation, investor relations, and business development as the company advances its lead oncology candidate, atebimetinib, in Phase 3 clinical trials.
Key Highlights
- Andrew Gengos appointed Chief Financial Officer, effective July 16, 2026.
- Mr. Gengos previously served as CFO of Terns Pharmaceuticals, acquired by Merck for $6.7 billion.
- He brings over 25 years of leadership experience in the biotechnology sector.
- Gengos will oversee financial strategy, capital allocation, investor relations, and business development.
- Immuneering's lead oncology candidate, atebimetinib, is in Phase 3 for first-line pancreatic cancer.
Price Impact
More from IMRX